Metastasis is the process by which cancer spreads from its primary location.
Parsortix was used to capture and assess circulating tumour cells (CTCs) – the tiny tell-tale signs of cancer. Researchers at the University of Texas MD Anderson Cancer Center then used a new technique called transmembrane receptor dynamics to distinguish between invasive cancer cells and less-invasive cells.
Being able to make such a distinction would allow doctors to offer more personalised treatments to patients.
The latest work by the team at the MD Anderson Cancer Center was published in the prestigious academic journal Nature.
"This study is the 19th peer-reviewed publication by a leading independent cancer centre demonstrating successful use of ANGLE's world leading Parsortix CTC system,” said the company’ chief executive, Andrew Newland.
“We are pleased to see new applications of the system being developed by independent users of Parsortix, all of which add to the body of evidence and generate new commercial opportunities."
Broker finnCap said the peer-reviewed article provided “further independent endorsement of the utility of Parsortix”.
The shares were trading 7.5p higher at 76p.
---adds broker quote and share pric---